Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Mitochondrial Metabolism and Apoptosis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VDAC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VDAC1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View VDAC1 Products |
| Gene Delivery | VDAC1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to preserve native mitochondrial outer membrane conformation. |
View VDAC1 Products |
| Benchmark Ab | Anti-VDAC1 Recombinant Antibody Recombinant positive control for western blot, IHC, and functional blocking. |
View VDAC1 Products |
| Validator | VDAC1 siRNA Set For knockdown verification and specificity controls in phenotypic assays. |
View VDAC1 Products |
| Related Target A | BCL2 Interacts directly with VDAC1 to regulate mitochondrial outer membrane permeabilization (MOMP) and apoptosis. |
View BCL2 Products |
| Related Target B | HK2 (Hexokinase 2) Binds VDAC1 to promote glycolysis (Warburg effect) and suppress apoptosis in cancer cells. |
View HK2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational integrity of beta-barrel structure | Lentivirus-driven stable cell lines for functional calcium flux and mitochondrial membrane potential assays. |
| Subfamily cross-reactivity screening (VDAC2, VDAC3) | Homolog panel proteins strictly verified by sequence and mass spectrometry. |
| Lack of reliable positive controls | Clinical-grade benchmark antibodies included in the catalog. |
| Off-target phenotypic false positives | Validated siRNA sets included for target-specific knockdown verification. |
Live VDAC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VDAC1 therapeutics is intensifying, with major players shifting focus from traditional global metabolic inhibitors to precision mitochondrial pore modulators. As first-generation therapies reach the clinic, the next wave of R&D is targeting VDAC1 oligomerization and protein-protein interactions (PPI) at the outer mitochondrial membrane.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors (e.g., VBIT-4) | Novus, Academic Spinoffs | Neurodegeneration, Lupus, Type 2 Diabetes | Oligomerization Assay (Need sequence-verified monomeric proteins) |
| Peptide Therapeutics (e.g., VDAC1-derived) | Biopharma Spinoffs | Solid Tumors, Glioblastoma | Protein-Protein Interaction (PPI) Inhibition (Need VDAC1-HK2/BCL2 binding assays) |
| siRNA / RNAi | Alnylam, Specialty Biotech | Refractory Cancers, Inflammatory Diseases | In vitro knockdown verification (Need high-potency siRNA sets) |